tiprankstipranks
TScan Therapeutics (TCRX)
NASDAQ:TCRX
US Market
TCRX
TScan Therapeutics
RESEARCH TOOLSreports
Want to see TCRX full AI Analyst Report?

TScan Therapeutics (TCRX) Stock Forecast & Price Target

409 Followers
See the Price Targets and Ratings of:

TCRX Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
TScan
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TCRX Stock 12 Month Forecast

Average Price Target

$6.00
▲(404.20% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for TScan Therapeutics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 404.20% change from the last price of $1.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.07,1.5261538461538462,1.9823076923076923,2.4384615384615387,2.894615384615385,3.350769230769231,3.806923076923077,4.263076923076923,4.719230769230769,5.1753846153846155,5.631538461538462,6.087692307692308,6.543846153846154,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.07,1.4492307692307693,1.8284615384615384,2.207692307692308,2.586923076923077,2.966153846153846,3.3453846153846154,3.724615384615385,4.1038461538461535,4.483076923076923,4.862307692307692,5.241538461538462,5.6207692307692305,{"y":6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.07,1.3723076923076922,1.6746153846153846,1.976923076923077,2.279230769230769,2.581538461538462,2.8838461538461537,3.1861538461538457,3.4884615384615385,3.7907692307692304,4.093076923076923,4.395384615384615,4.697692307692307,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.22,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7.00Average Price Target$6.00Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on TCRX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$6
Buy
404.20%
Upside
Reiterated
06/23/26
TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
H.C. Wainwright Analyst forecast on TCRX
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$7
Buy
488.24%
Upside
Reiterated
06/23/26
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
Wedbush Analyst forecast on TCRX
David Nierengarten
Wedbush
Wedbush
$5
Buy
320.17%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), TScan Therapeutics (NASDAQ: TCRX) and PACS Group Inc (NYSE: PACS)
Needham Analyst forecast on TCRX
Gil Blum
Needham
Needham
$6
Buy
404.20%
Upside
Reiterated
06/23/26
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)
Morgan Stanley Analyst forecast on TCRX
Maxwell Skor
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
06/22/26
Analysts Conflicted on These Healthcare Names: TScan Therapeutics (NASDAQ: TCRX), Exelixis (NASDAQ: EXEL) and AbbVie (NYSE: ABBV)
TD Cowen Analyst forecast on TCRX
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/11/26
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF)
BTIG Analyst forecast on TCRX
Justin Zelin
BTIG
BTIG
―
Hold
―
Reiterated
12/09/25
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (NASDAQ: TERN) and TScan Therapeutics (NASDAQ: TCRX)
Barclays Analyst forecast on TCRX
Peter Lawson
Barclays
Barclays
$3
Buy
152.10%
Upside
Reiterated
11/04/25
Barclays Reaffirms Their Buy Rating on TScan Therapeutics (TCRX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on TCRX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$6
Buy
404.20%
Upside
Reiterated
06/23/26
TScan Therapeutics: Early ALLOHA Phase 1 Efficacy and Safety Reinforce Late-Stage Plans; Buy Rating and $6 Price Target Maintained
H.C. Wainwright Analyst forecast on TCRX
Andres Y. Maldonado
H.C. Wainwright
H.C. Wainwright
$7
Buy
488.24%
Upside
Reiterated
06/23/26
TScan Therapeutics: ALLOHA Data, Streamlined Manufacturing Bolster Buy Rating with $7 Price Target Maintained
Wedbush Analyst forecast on TCRX
David Nierengarten
Wedbush
Wedbush
$5
Buy
320.17%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), TScan Therapeutics (NASDAQ: TCRX) and PACS Group Inc (NYSE: PACS)
Needham Analyst forecast on TCRX
Gil Blum
Needham
Needham
$6
Buy
404.20%
Upside
Reiterated
06/23/26
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Relmada Therapeutics (RLMD)
Morgan Stanley Analyst forecast on TCRX
Maxwell Skor
Morgan Stanley
Morgan Stanley
―
Hold
―
Reiterated
06/22/26
Analysts Conflicted on These Healthcare Names: TScan Therapeutics (NASDAQ: TCRX), Exelixis (NASDAQ: EXEL) and AbbVie (NYSE: ABBV)
TD Cowen Analyst forecast on TCRX
Tara Bancroft
TD Cowen
TD Cowen
―
Buy
―
Reiterated
03/11/26
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF)
BTIG Analyst forecast on TCRX
Justin Zelin
BTIG
BTIG
―
Hold
―
Reiterated
12/09/25
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (NASDAQ: TERN) and TScan Therapeutics (NASDAQ: TCRX)
Barclays Analyst forecast on TCRX
Peter Lawson
Barclays
Barclays
$3
Buy
152.10%
Upside
Reiterated
11/04/25
Barclays Reaffirms Their Buy Rating on TScan Therapeutics (TCRX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering TScan Therapeutics

3 Months
Gil BlumNeedham
Success Rate
6/15 ratings generated profit
40%
Average Return
-3.56%
Copying Gil Blum's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -3.56% per trade.
1 Year
Gil BlumNeedham
Success Rate
7/15 ratings generated profit
47%
Average Return
-18.19%
Copying Gil Blum's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -18.19% per trade.
2 Years
Gil BlumNeedham
Success Rate
8/15 ratings generated profit
53%
Average Return
-16.60%
Copying Gil Blum's trades and holding each position for 2 Years would result in 53.33% of your transactions generating a profit, with an average return of -16.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TCRX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
5
8
11
11
8
Buy
1
1
1
0
0
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
10
13
12
9
In the current month, TCRX has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TCRX average Analyst price target in the past 3 months is 6.00.
Each month's total comprises the sum of three months' worth of ratings.

TCRX Financial Forecast

TCRX Earnings Forecast

Next quarter’s earnings estimate for TCRX is -$0.25 with a range of -$0.44 to -$0.18. The previous quarter’s EPS was -$0.22. TCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year TCRX has Performed in-line its overall industry.
Next quarter’s earnings estimate for TCRX is -$0.25 with a range of -$0.44 to -$0.18. The previous quarter’s EPS was -$0.22. TCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year TCRX has Performed in-line its overall industry.

TCRX Sales Forecast

Next quarter’s sales forecast for TCRX is $1.88M with a range of $0.00 to $2.50M. The previous quarter’s sales results were $982.00K. TCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year TCRX has Performed in-line its overall industry.
Next quarter’s sales forecast for TCRX is $1.88M with a range of $0.00 to $2.50M. The previous quarter’s sales results were $982.00K. TCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year TCRX has Performed in-line its overall industry.

TCRX Stock Forecast FAQ

What is TCRX’s average 12-month price target, according to analysts?
Based on analyst ratings, TScan Therapeutics’s 12-month average price target is 6.00.
    What is TCRX’s upside potential, based on the analysts’ average price target?
    TScan Therapeutics has 404.20% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TCRX a Buy, Sell or Hold?
          TScan Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is TScan Therapeutics’s price target?
            The average price target for TScan Therapeutics is 6.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $7.00 ,the lowest forecast is $5.00. The average price target represents 404.20% Increase from the current price of $1.19.
              What do analysts say about TScan Therapeutics?
              TScan Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of TCRX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.